Status:
ACTIVE_NOT_RECRUITING
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation
Lead Sponsor:
University Hospital, Lille
Conditions:
Pneumonia, Ventilator-Associated
Pneumonia, Hospital-Acquired
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
RESPIRE is a randomized, unblinded, controlled study to measure the impact of a strategy based on a PCR test on the adjustment of antimicrobial therapy in immunocompromised patients suspected with ven...
Eligibility Criteria
Inclusion
- Adult immunocompromised patients hospitalized in ICU with suspected VAP or HAP requiring MV
Exclusion
- No immunodeficiency Moribund patients (SAPS II \> 90) Pregnant women Refuse to participate to the study
Key Trial Info
Start Date :
March 28 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2028
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT05405491
Start Date
March 28 2023
End Date
March 1 2028
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Houard
Lille, France